Investor Presentaiton

In sum, we believe Coloplast can continue to deliver stable shareholder returns through ... Organic growth and EBIT margin development Highlights 12% 28% • Stable market trends in our Chronic Care business 7% 07/08 09/10 11/12 13/14 15/16 17/18 19/20 21/22 YTD 22/23 Organic growth EBIT Margin² 10% 8% 07/08 09/10 11/12 FCF and ROIC development 8% 19% Innovative product portfolio and new product launches Strong Coloplast Care retention program and innovative DtC activities • Increased focus on growing the business outside Europe Selective acquisitions in long-term growth businesses, which support long-term value creation (Atos Medical, Kerecis) • Additional improvements in manufacturing • • by leveraging global operations footprint European leverage will provide funds for further investments in sales initiatives Resulting in strong free cash flow generation and high return on invested capital ROIC FY 21/22 and 9M 22/23 impacted by the recent acquisition of Atos Medical 12% 13/14 15/16 17/18 19/20 21/22 YTD 22/23 - FCF to sales¹ ROIC after tax² 1) FCF adjusted for Mesh payments and acquisitions (2016/17, 2017/18, 2020/21, 2021/22). YTD 2022/23 adjusted for payment related to the formal resolution of the US Veteran Affairs matter. 2) Before special items. Special items expenses of DKK 5 million in 9M 2022/23 44 Coloplast

View entire presentation